**Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC)**

Shicheng Guo1,5, Fengyang Yan1, Jibin Xu2, Yang Bao3, Ji Zhu4, Xiaotian Wang1, Junjie Wu1,5, Yi Li1, Weilin Pu1, Yan Liu6, Zhengwen Jiang6, Yanyun Ma1, Xiaofeng Chen7, Momiao Xiong8, Li Jin1,9, Jiucun Wang1,9

1 State Key Laboratory of Genetic Engineering and Ministry of Education Key Laboratory of Contemporary Anthropology, Collaborative Innovation Center for Genetics and Development, School of Life Sciences and Institutes of Biomedical Sciences, Fudan University Jiangwan Campus, Shanghai 200438, China

2 Department of Cardiothoracic Surgery, Changzheng Hospital of Shanghai, Shanghai, China

3 Yangzhou No.1 People's Hospital, Yangzhou, China

4 Department of Cardiothoracic Surgery, Changhai Hospital of Shanghai, Shanghai, China

5 Department of Pneumology, Changhai Hospital of Shanghai, Shanghai, China

6 Center for Genetic & Genomic Analysis, Genesky Biotechnologies Inc., Shanghai, China

7 Department of Cardiothoracic Surgery, Huashan Hospital, Fudan University, Shanghai, China

8 Human Genetics Center, The University of Texas School of Public Health, Houston, Texas

9 Fudan-Taizhou Institute of Health Sciences, 1 Yaocheng Road, Taizhou, Jiangsu 225300, China

**Run title**: Novel panel of DNA methylation biomarkers for NSCLC diagnosis

Figures counts: 2

Table counts: 3

Abstract counts: 202

Mainbody counts: 3671

Email:

|  |  |
| --- | --- |
| Shicheng Guo | [Shicheng.Guo@hotmail.com](mailto:Shicheng.Guo@hotmail.com) |
| Fengyang Yan | yanfengyang1990@gmail.com |
| Jibin Xu | jibinx@yahoo.com |
| Yang Bao | baoyangdr@gmail.com |
| Ji Zhu | [luckypig222@163.com](mailto:luckypig222@163.com) |
| Xiaotian Wang | wangxiaot@gmail.com |
| Junjie Wu | wjjxcc@126.com |
| Yi Li | liyidadi19891124@gmail.com |
| Weilin Pu | puweilin@gmail.com |
| Yan Liu | liuyan@geneskies.com |
| Zhengwen Jiang | zhengwenj@geneskies.com |
| Yanyun Ma | mayymail@gmail.com |
| Xiaofeng Chen | cfx3166@126.com |
| Momiao Xiong | [momiao.xiong@gmail.com](mailto:momiao.xiong@gmail.com) |
| Li Jin | [lijin.fudan@gmail.com](mailto:lijin.fudan@gmail.com) |
| Jiucun Wang | jcwang@fudan.edu.cn |

Corresponding authors:

Li Jin, National Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai 200438, China, Phone: +86-21-51630607, Fax: +86-21-51630607, E-mail: [lijin.fudan@gmail.com](mailto:lijin.fudan@gmail.com)

Jiucun Wang, National Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai 200433, China, Phone: +86-21-51630606, Fax: +86-21-51630607, E-mail: [jcwang@fudan.edu.cn](mailto:jcwang@fudan.edu.cn).

**Abstract:**

**[Background]** DNA methylation was suggested as the promising biomarker for lung cancer diagnosis. However, it is a great challenge to search for the optimized combination of the methylation biomarkers to obtain the maximum diagnosis performance. **[Result]** In this study, we developed a panel of DNA methylation biomarkers and validated their diagnostic efficiency for non-small cell lung cancer (NSCLC) in a large Chinese Han NSCLC retrospective cohort. Three high-throughput DNA methylation microarray dataset (458 samples) were collected in the discovery stage. After normalization, batch effect elimination and integration, significant differentially methylated genes and the best combination of the biomarkers were determined by leave-one-out SVM (support vector machine) feature selection operation. Then candidate promoters were examined by MSD-SNuPET (methylation status determined single nucleotide primer extension technique) in an independent set of 150 pairwise NSCLC/normal tissues. Four statistical models with 5-fold cross-validation were used to evaluate the performance of the discriminatory algorithms. The sensitivity, specificity and accuracy were 86.3%, 95.7% and 91%, respectively in Bayes tree model. The logistic regression model incorporated five gene methylation signatures at AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, adjusted for age, gender and smoking showed robust performance in which the sensitivity , specificity, accuracy, and area under the curve (AUC) were 78%, 97%, 87%, and 0.91, respectively. **[Conclusion]** In summary, a high throughput DNA methylation microarray dataset followed by batch effect elimination can be a good method to discover optimized DNA methylation diagnostic panels. Methylation profiles of AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, could be an effective methylation-based assay for the NSCLC diagnosis.

**Key words**: Non-small cell lung cancer, DNA methylation, Biomarker, Batch effect elimination, Diagnosis

## Background

Lung cancer, a complex disease involving both genetic and epigenetic changes, is the leading cause of cancer deaths worldwide [[1](#_ENREF_1)]. About 80% of primary lung cancers are non-small cell lung carcinoma (NSCLC) that are characterized by a long asymptomatic latency and poor prognosis. While the overall 5-year survival rates for late stage III and IV of NSCLC patients were just 5%-14% and 1% respectively, the rate could increase to 50% for the early stage of the NSCLC patients who are typically treated with surgery [[2](#_ENREF_2)]. Many imaging and cytology-based strategies have been employed in NSCLC diagnosis; however none of them have yet been proven completely effective in reducing the mortality. The advances in molecular profiling of NSCLC over the past decade have made a paradigm shift in its diagnosis and treatment.

Among all the genetic variations, single nucleotides polymorphisms (SNPs) have been considered as the most stable biomarker for heritable disease, since the status of the SNPs can be detected with almost 100% accuracy and unchanged during the entire life. It is specific and powerful for single gene caused disease. However, for complex diseases, such as cancers, the prediction power of SNPs is limited. The plethora of studies have shown that AUCs of the prediction model based on significant SNPs can confer only 0.54-0.55 for non-small cell lung cancer [[3](#_ENREF_3)] and 0.54-0.60 for thyroid cancer [[4](#_ENREF_4)], which has been considered as one of highest familial risk carcinomas among all kinds of cancers. Molecular biomarkers such as mRNA, microRNA and protein for NSCLC diagnosis have been developed and investigated in the past decades. However, their accuracy for diagnosis of NSCLC is far from reaching clinical implementations, in which >90% sensitivity and specificity of diagnosis should be guaranteed.

DNA methylation that is one of the most important mechanism involved in genes and MicroRNAs expression regulation [[5](#_ENREF_5)], gene alternative splicing [[6](#_ENREF_6)], play important roles in the early stage of cancer. Because it is stable and easily detected qualitatively or quantitatively, DNA methylation was taken as the most promising diagnostic marker for the early detection of cancer[[7](#_ENREF_7), [8](#_ENREF_8)], are compared with SNP/mutation [[4](#_ENREF_4)], CNVs [[9](#_ENREF_9)] and gene/microRNA expression [[10](#_ENREF_10)]. Hundreds of aberrant DNA methylation changes in the early stage of NSCLC have been identified in the past decades [[11](#_ENREF_11), [12](#_ENREF_12)]. However, despite several diagnostic panels have been developed [[13](#_ENREF_13)], these studies on DNA methylation in NSCLC were still limited by their small sample size, low number of selected genes and qualitative rather than quantitative DNA methylation. These limitations would cause low reproducibility of the assay and explain why the majority of these studies could not be replicated.

In our previous study, we found the prediction ability is limited when the prediction model only includes the methylation status of a single gene, even for classic tumor suppressor gene [[14](#_ENREF_14)].  A diagnostic panel with several genes would be a promising approach to achieve better prediction performance for the clinical utility. Methylation microarrays measure the methylation levels of thousands of genes in a single assay. It is a revolutionary tool for identifying genes whose methylation changes in response to specific situation, such as different development stages, physiological or pathological status and provide fundamental data for feature selection to construct the best combination of the predictive variables. In addition, a large number of public methylation microarray datasets have been shared in certain database, such as Gene Expression Omnibus (GEO). The stability and reproducibility of the prediction model would be significantly increased when multiple datasets with same study-design were pooled-together. However, methylation array results can be greatly affected by a variety of non-biological variables, such as methods for DNA isolation, bisulfite conversion, probe processing and scanning, reagents from different companies, different technicians or even different atmospheric ozone levels. Usually, the term “batch” refers to microarrays processed at one site over a short period of time using the same platform. The cumulative error introduced by these time, place and situation-dependent variations is referred to as batch effects. In terms of different study, the methylation microarray data were created in different times, places, and by different technicians and so on, therefore, the main variation among data would be shown as batch effect. In our previous study, we found that the Combat algorithm could remove such noise (batch signal or each individual study) from the dataset with powerful efficiency, adjusted with additional and multiple effects of the batch information [[15](#_ENREF_15), [16](#_ENREF_16)], which provides the prerequisite to combine the methylation array dataset to increase the sample size of the statistical analysis.

In the present study, we first systematically integrated three independent high-throughput DNA methylation datasets from the GEO [[17](#_ENREF_17)] and TCGA projects (**Supplementary Table 1**). Optimized DNA methylation combination was established through feature selection procedure after preliminary normalization and batch effect elimination with the Combat algorithm among the datasets to maximum the NSCLC prediction performance. Five gene methylation statuses at *AGTR1*, *GALR1*, SLC5A8, *ZMYND10* and *NTSR1* were identified to be the most powerful combination for the NSCLC prediction. Then, to further evaluate their performance for diagnosis, we designed a novel methylation status determined single nucleotide primer extension technique (MSD-SNuPET) for the simultaneous quantification of methylation at these five methylated loci. These five significant differentially methylated genes were used to validate the results in 150 pairs of NSCLC and normal tissues from a Chinese Han population with MSD-SNuPET.

## Results

**Public dataset collection, Batch effect elimination and candidate gene selection**

NSCLC related public DNA methylation microarrays were searched through the Gene Expression Omnibus (GEO), ArrayExpress and TCGA projects. In total, 3 independent NSCLC datasets were created with a total of 458 microarrays which included 352 NSCLC and 106 normal tissues **(Figure 1 and Supplementary Table 1)**. Batch effect significantly existed among the datasets which was showed in the first and second principle components. We observed that the samples were clustered mainly by studies rather than tumor and normal tissue samples **(Figure 2A)**. *ComBat*, an empirical Bayes method, were used to eliminate the batch effects after quantile normalization to three datasets. As a result, batch effect was largely removed by *Combat* **(Figure 2B)**. In addition, as the hierarchical cluster analysis showed, biological information was highly preserved after batch effect elimination (**Supplementary Figure 2**). SVM were used to conduct feature selection and assess the prediction abilities with leaving-one-out cross-validation. The accuracy of the SVM for classifying NSCLC was 98.98%, in the test set. Among the 112 shared probes, five CpG sites (*NTSR1*, *SLC5A8*, *GALR1*, *AGTR1* and *ZMYND10*) were selected in the feature selection stage. We found these five genes were significantly differentially methylated between the tumor and normal tissue samples. In detail, meta-analysis of the DNA methylation microarrays showed that *NTSR1* (P-value = 5.4×10-15), *SLC5A8* (P-value = 5.9×10-9), *GALR1* (P-value = 9.9×10-10) and *AGTR1* (P-value = 6.7×10-5) were significantly hypermethylated in NSCLC while *ZMYND10* (P-values = 6.2×10-20) was significantly hypomethylated in NSCLC **(Supplementary Figure 3)**. These results suggested that the selected five predictors would be potential biomarkers for the NSCLC diagnosis. To further evaluate their performance for diagnosis of NSCLC, we developed a panel of these five DNA methylation biomarkers and validated their diagnostic efficiency in 150 paired NSCLC and normal tissue samples in China.

**Methylation status validation with MSD-SNuPET**

In order to validate the results from Meta-analysis, methylation status of the above 5 genes were detected with MSD-SNuPET in 150 pairs of NSCLC and adjacent normal tissues. The characteristics of patients were showed in **Table 1**. Consistent with the microarray data, the absolute DNA methylation percentage of these five genes were significantly differentially methylated between NSCLC and normal tissues (**Table2**, **Figure 2C-2I**). Logistic regression analysis showed that hypermethylated *NTSR1*, *SLC5A8*, *GALR1*, *AGTR1* and hypomethylated *ZMYND10* were significantly associated with the NSCLC risk adjusted for age, gender and smoking status with the P-value of 5.9×10-7, 7.8×10-9, 2.3×10-6, 1.3×10-6, and 5.2×10-8, respectively **(Table 2)**. MSD-SNuPET results showed the methylation of *LINE-1* was significantly lower in NSCLC than normal tissue (*t*-test, P-value = 2.39×10-12). Additionally, DNA methylation of *LINE-1* was significantly associated with gender (R2=0.18, P-value=0.0087), which was highly consistent with the previous reports about the methylation status of this gene [[18](#_ENREF_18), [19](#_ENREF_19)], suggesting the highly credibility of MSD-SNuPET. The prediction ability for each gene separately was also evaluated by logistic regression. Moderate prediction ability were identified, in which sensitivity ranges from 44.3% to 73.15%; specificity ranges from 79.59% to 94.56% and AUC ranges from 0.67 to 0.80 (Table 2). Correlation analysis showed that there was no co-methylation among the five genes. In addition, no significant association was observed between any of the 5 genes with age, smoking, TNM stage, lung cancer differentiation and lung cancer subtype (Ad or Sc) in both univariate and multivariate association models in our study. However, significant association between gender and *SLC5A8* (P-value=0.0001), *ZMYND10* (P-value=0.045) were identified which might indicate a specific biological mechanism of *SLC5A8* and *ZMYND10* in the tumorigenesis of NSCLC. Protein-protein interaction networks from *String 9.0* showed that there were comprehensive networks for both *NTSR1* and *GALR1*. The majority of these genes were cancer related genes, which has been reported to play important roles in cancer initiation, progress or therapy, such as *S100A9*, *NGF*, *TAC1*, *CCK*, *FPR2*, *ADRA1B*, and *CCL21* in the gene-gene interaction networks (**Supplementary Figure 4**).

**Sensitivity, specificity and accuracy of the diagnosis panel**

Several classification methods including logistic regression model, random forest, support vector machine (SVM), and Bayes tree were used to construct effective diagnosis models for cancer prediction based on MSD-SNuPET results. No significant unbalances were found in the train and test dataset, which suggested the prediction models were creditable and stable. Five-fold cross validation was used to evaluate the performance of the classifiers. As a result, Bayes tree was the most powerful model for the diagnosis of NSCLC, whose sensitivity (Sen), specificity (Spe) and classification accuracy (Acc) were 86%, 96% and 91% (Table 3), respectively. Other classification methods had similar performance and the worst classifier was the logistic regression. However, even the logistic regression model incorporated the same five genes mentioned above, the sensitivity, specificity, classification accuracy, and area under the curve (AUC) could reach 78%, 97%, 87%, and 0.906 (95% CI: 0.89-0.91), respectively, after adjusted for age, gender and smoking. The logistic regression still showed the potential diagnostic significance of the five methylated genes. In addition, prediction abilities between smoking and non-smoking, adenocarcinoma and squamous cell carcinoma, early stage (I and II) and late stage (III and IV), and well or moderate and poor differentiation population were assessed under Bayes tree model. We found there is no significant differential performance between smoking (Acc=92.1%, 95% CI: 90.6%-93.6% ) and non-smoking (Acc=0.939, 95% CI: 0.935-0.943), adenocarcinoma (Acc=0.82, 95% CI: 0.72-0.92) and squamous cell carcinoma (Acc=0.94, 95% CI: 0.87-0.95), early stage (Acc=0.87, 95% CI: 0.75-0.87) and late stage (Acc=0.92, 95% CI: 0.82-0.92), while a significant difference (permutation test, P<10-10) was found between well or moderate (Acc=0.9, 95% CI:0.83-0.91) and low differentiation population (Acc=0.73, 95% CI: 0.5-0.74), which suggested further research should be considered.

## Discussion

NSCLC early diagnosis and corresponding surgical intervention are taken as the most effective method to increase the survival time and to decrease the mortality from NSCLC death. Since the global change of DNA methylation occurred in the beginning of the carcinogenesis, DNA methylation has been considered as the most powerful biomarker for early detection, even screening [[20](#_ENREF_20)]. In the present study, the two stage biomarker discovery pipeline was applied to optimize the combination of DNA methylation biomarkers for NSCLC diagnosis. The optimal biomarker combination was identified using 107 genes in a large discovery dataset. A novel DNA methylation diagnosis panel of five genes (*NTSR1*, *SLC5A8*, *GALR1*, *AGTR1* and *ZMYND10*) was identified. The DNA methylation diagnosis panel was then validated in another independent NSCLC study. A multi-loci DNA methylation detection method (MSD-SNuPET), was conducted to determine the absolute quantitative methylation level of the five genes in 150 pairs of NSCLC and adjacent normal tissues from a Chinese Han population. In the validation stage, the Bayes tree model shows the highest sensitivity, specificity and accuracy for NSCLC diagnosis based on the five genes which is potential for clinical application.

It is important that five candidate biomarkers have been investigated widely in cancer research. Neurotensin receptor-1 (*NTSR1*) is a G-protein coupled receptor (*GPCR*). It has been widely reported to be associated with carcinogenesis, cancer progression [[21](#_ENREF_21)] and prognosis [[22](#_ENREF_22), [23](#_ENREF_23)]. Previous evidence showed the potential use of the *NTSR1* as a biomarker for cancer progression and as a component of personalized medicine in selective cancers [[24](#_ENREF_24)] which is consistent with our present result. *GALR1*, galanin receptor subtype 2, suppresses cell proliferation in several cancers such as head and neck [[25](#_ENREF_25), [26](#_ENREF_26)], oral squamous cell carcinoma [[27](#_ENREF_27)]. Gene expression inactivation of *GALR1* can be caused by promoter hypermethylation [[25](#_ENREF_25)]. Meanwhile, *GALR1* has also been a subtype determining gene in breast cancer which suggests the potential powerful role in cancer diagnosis. *SLC5A8* (solute carrier family 5, member 8) is a tumor suppressor gene and is usually suppressed in colon, and gastric cancers [[28-30](#_ENREF_28)]. *ZMYND10* (Zinc finger, MYND-type containing 10) has recently been identified as a candidate tumor suppressor gene due to the occurrence of missense mutations and loss of its expression in lung cancer.

Multi-cellular issue is a great challenge in epigenetic studies. On one side, cancer tissues include cancer cells (epithelial cells), mesenchymal cells and so on. However, the proportion (at least 70% in general) of the tumor cells in cancer tissue is always much significantly higher than that of other cells. On the other side, normal tissues also include epithelial cells, mesenchymal cells and some others. In the present study, the null hypothesis is that the methylation level in the cancer tissue (mixed cells) is the same with normal tissue (mixed cells). The alternative hypothesis is that the methylation level in the cancer tissue (mixed cells) is different from normal tissue (mixed cells). We used the paired *t*-test to test the difference in the mean of the methylation between cancer tissue and normal tissue. The background or the noises from the adjacent non-cancer cells could be adjusted from the cancer cells when the methylation profiles of the corresponding cells were established.

All the results in the present study were based on quantitative signals of the DNA methylation. We also conducted analyses which were based on discrete DNA methylation signals in which beta values < 0.2 were defined as the un-methylated CpGs; beta values > 0.8 were defined as the full methylated CpGs and beta values between 0.2-0.8 defines semi-methylated CpGs. In this condition, five genes were still significantly differential methylation between NSCLC and normal tissues. No significant changes were found in classification sensitivity, specificity and accuracy. Also, the sensitivity, specificity and AUC of diagnosis with one gene added to the model each time were summarized in the Supplementary Figure 5 in which we found the sensitivity and AUC were gradually increased step by step.

Lung cancer diagnosis is a challenging problem. In order to discover a potential panel of DNA methylation-based biomarkers for diagnosis of NSCLC, we should perform a genome-wide search for an optional combination of tens or hundreds of loci from the genome-wide DNA methylation profile. Integration analysis to inter-platform genome-wide DNA methylation datasets with appreciated data normalization and batch effect elimination could provide optimal biomarker combinations in a large sample population to obtain maximum diagnosis efficiency. With this approach, we identified a 5 gene signature including *AGTR1*, *GALR1*, *SLC5A8*, *ZMYND10* and *NTSR1*, which could provide high diagnostic sensitivity and specificity.

## Conclusion

Integrated analysis of multiple-platform high throughput DNA methylation microarray datasets followed by batch effect elimination is a good approach to discover diagnostic biomarker panels for NSCLC. Methylation profiles of *AGTR1*, *GALR1*, *SLC5A8*, *ZMYND10* and *NTSR1*, would be an effective methylation-based assay for the NSCLC diagnosis.

## Materials and Methods

**Study design and pipeline description**

Public high-throughput microarray databases which include GEO and ArrayExpress were searched to collect NSCLC related DNA methylation microarray data. Non-small cell lung cancer and/or methylation were taken as the key words in the retrieving procedure. Although larger number studies have been conducted in NSCLC biomarker research, only two GSE records were retrieved, including GSE16559 and GSE28094. GSE16559 with 57 NSCLC and 52 normal tissue samples were to discover aberrant DNA methylation in lung adenocarcinoma and mesothelioma. GSE28094 with 33 NSCLC and 3 normal tissue samples were designed to make the DNA Methylation fingerprint with 1,628 human samples in different tissues and status. Both of these two datasets were based on the *Illumina GoldenGate* platform which includes 371 genes with 1,536 loci. Additionally, the CGA project is another comprehensive study which included 262 NSCLC and 51 normal tissue samples. Infinium methylation 27K with 14, 495 genes and 27,578 loci were used to perform the DNA methylation profiling. The common number of DNA methylation genes shared by two methylation microarray platforms were 107 genes (112 probes). Eventually, DNA methylation profiling data of 458 NSCLC associated samples (352 NSCLC and 106 normal tissue) were obtained from the above three public datasets. These data will be taken as the primary data in the biomarker discovery stage (**Supplementary Table 1**).

When the microarray is provided as fluorescent signals, the gene methylation level was calculated with the fluorescent signals of methylation and un-methylation alleles by the traditional function of beta, where M and U represent the signal intensities for about 30 methylated (M) and un-methylated (U) probes on the array. Background-correction was conducted with recommended methods for each platform. K-nearest neighbor imputation (KNN imputation) was performed to deal with the missing values. 112 probes were shared between these two microarray platforms. DNA methylation signals of these probes were combined for all the samples. Quantile normalization was applied to combine all the data from different studies. To further reduce biases, we use the batch effect elimination tool, *ComBat*, to eliminate the batch effects that exist in independent datasets [[15](#_ENREF_15)]. In the present study, we use the principal component analysis (PCA) to visualize the extension of the elimination of batch effect by observing the batch information distribution in the two-dimension plot of principle component 1 (PC1) and principle component 2 (PC2). The data adjusted by the *Combat* was then used for feature selection procedure in classification and differential methylation analysis. Feature selection was conducted by random forest and SVM with leave-one cross-validation. Differential methylation analysis was conducted by Wilcox signed-rank test without normality assumption. The most powerful panel was identified and the differential methylation status was estimated. In the validation stage, the methylation status of genes from the above panel (methylation genes combination) was detected in 150 NSCLC and normal tissues from the Chinese Han population by MSD-SNuPET. Logistic regression model, random forest, support vector machine (SVM), and Bayes tree were used to classify NSCLC in the validation data with five-fold cross-validation.

**Patients, samples and DNA**

NSCLC samples and corresponding normal lung tissues for validation study in the Chinese population were obtained from 150 patients who underwent pulmonary resection for primary NSCLC at Changhai Hospital, Shanghai, China. The study was approved by Fudan University and Changhai Hospital and informed consents were obtained from the patients. Exclusion criteria included subjects with a family history of lung cancer, previous radiotherapy, and chemotherapy or adjuvant therapy before surgery. All tissues were immediately frozen at -80℃ after surgical resection. Histological examination and tumor-node-metastasis classification were conducted according to World Health Organization classification criteria [[31](#_ENREF_31)] and AJCC Cancer Staging Manual, 7th Edition [[32](#_ENREF_32)], respectively. Age, gender, smoking status, histology type, TNM stage and differentiation status were collected as the covariates when conducting association between DNA methylation and disease status. Smoking status was assigned to binary status: never and ever smoking. TNM stage was assigned to early stage (I and II) or late stage (III and IV) when it is necessary so that the sample size can be big enough to get the efficient statistic power.

**MSD-SNuPET: Methylation status dependent single nucleotide primer extension assay**

DNA extraction and Bisulfite conversion were performed as previously described [[33](#_ENREF_33), [34](#_ENREF_34)]. Methylation status determined by the single nucleotide primer extension technique (MSD-SNuPET) was designed for the quantification of methylation at multiple methylated loci simultaneously. MSD-SNuPET was developed based on SNPshot technology to bisulfite converted CpG sites. Un-methylated cytosine would be converted to uracil when treated with bisulfite while methylated cytosine maintains as the cytosine. Therefore, methylation status detection can be detected by specific primer and PCR amplification. Primer 3.0 was used to design primer sets (called amplifying primer) which were applied to amplify genome regions including the target CpG sites. Allele-specific elongation primer was used to quantify the copy number of C and T alleles. Primer pairs were showed in **Supplementary Table 2**. PCR was performed in a final volume of 10 μL containing 1x HotStarTaq buffer, 3.0 mM Mg2+, 0.3 mM dNTP, 1 U HotStarTaq polymerase (Qiagen Inc. USA), 1 µl DNA template and 1µl multiple primer set. Amplifications were conducted in a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA) with the following thermal cycling profile: denaturation for 2 min at 95°C, followed by 11 cycles, each consisting of 20 sec at 94°C, 40 sec at 60°C, 90 sec at 72°C, and a final extension step for 2 min at 72°C, respectively. Negative and positive controls were included in each run of PCR as described above. The products of the sequencing reactions were purified and SNaPshot analysis of single nucleotides extension for multiple loci operation was shown as in our previous works [[35](#_ENREF_35)]. DNA sequencing was conducted with the 3730 DNA analyzer. GeneMapper 4.1 (Applied Biosystems, Co., Ltd., USA) was used to analysis the fluorescence signals that represent different alleles. DNA methylation level is positively correlated with the magnitude of the C allele () and negative corrected with the magnitude of the T allele () in MSD-SNuPET technique (**Supplementary Figure 1**). In order to quantitatively estimate the methylation level for each CpG site, standard calibration curve was established, in which synthetic DNA fragments of C and T alleles were mixed with C allele proportion at 10%, 20%, 30%, 35%, 40%, 50%, 60%, 70%, 75%, 80% and 90%, respectively. Then, a standard calibration curve could be fitted as a quadratic regression model: , in which and are optimized parameters. indicates the ratio of and alleles (). In the present study, one technique and biological control were set. The reference site was a C site that was not in the CpG site, therefore a low methylation signal should be detected and non-significant association should be detected between cancer and normal samples. Methylation status of *LINE-1* was taken as a biological control since we are clear that it is hypo-methylation in the cancer tissues.

**Statistical analysis and machine learning**

We select methylated genes for classification by ranking genes with P-values for testing differential methylation between tumor and normal tissue samples. We use three test statistics: student -test, Wilcoxon rank sum test and Wilcoxon signed rank test statistic to test for differential methylation between two conditions for the normal distribution of methylation level, non-paired tumor and normal tissue samples and paired tumor and normal tissue samples, respectively. False discovery rate (FDR) correction was used for multiple test correction with the R function of p.adjust with fdr as a parameter. Euclidean distance and partitioning around medoids were used to conduct hierarchical cluster analysis. Logistic regression (Package stats), support vector machine (SVM, Package e1071), random forest based classification (Package randomForest) and Bayes tree (Package BayesTree) were used to classify the NSCLC tumor and normal tissues. The optimized prediction model was built with the best prediction accuracy in the training dataset and then the sensitivity, specificity, accuracy were obtained from logistic regression, SVM, random forest and Bayes tree model in the test dataset with previous parameters applied in the training stage. All statistical analyses were conducted in R [[36](#_ENREF_36)]. Protein-protein interaction networks were constructed by *String 9.0* to show the function network of the genes in our study [[37](#_ENREF_37)].

**Abbreviations:**

NSCLC: non-small cell lung cancer

MSD-SNuPET: methylation status determined single nucleotide primer extension technology

AUC: area under the curve

TCGA: the cancer genome atlas project

*AGTR1*: angiotensin II receptor, type 1

*GALR1*: galanin receptor 1

*NTSR1*: neurotensin receptor 1

*SLC5A8*: solute carrier family 5, member 8

*ZMYND10*: zinc finger, MYND-type containing 10

*LINE-1*: long interspersed element-1

## Competing interests

ZJ and YL are the founders and employees of Genesky Biotechnologies, respectively.

## Authors’ contributions

SG, JW, and LJ contributed to the conception, design and final approval of the submitted version. SG contributed to the integrated analysis of multiple microarray datasets, batch effect elimination and the statistical analysis. FY conducted bisulfite treatment of DNA. All authors read and approved the final manuscript. JX, YB, JZ, XW, and JW collected samples and helped to draft the manuscript. YL, WP, MX helped in data cleaning and statistical analysis. YL, ZJ helped to conduct MSD-SNuPET. All authors read and approved the final manuscript.

## Acknowledgements

We thank all participating subjects for their kind cooperation in this study. We thank Dr. Hongyan Xu (Department of Biostatistics and Epidemiology, Georgia Regents University) and Dr. Yan Sun (Department of Biomedical Informatics, School of Medicine, Emory University) for their critical review and comments. This research was supported by the Science and Technology Committee of Shanghai Municipality (11DJ1400102), National High-Tech Research and Development Program (2012AA021802), National Science Foundation of China (NSFC, 81172228, 30890034), Ministry of Science and Technology (2011BAI09B00), and 111 Project (B13016). The computations involved in this study were supported by Fudan University High-End Computing Center.

## Reference

1. Siegel R, Naishadham D, Jemal A: **Cancer statistics, 2012.** *CA Cancer J Clin* 2012, **62:**10-29.

2. Hankey BF, Ries LA, Edwards BK: **The surveillance, epidemiology, and end results program: a national resource.** *Cancer Epidemiol Biomarkers Prev* 1999, **8:**1117-1121.

3. Li H, Yang L, Zhao X, Wang J, Qian J, Chen H, Fan W, Liu H, Jin L, Wang W, Lu D: **Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model.** *BMC Med Genet* 2012, **13:**118.

4. Guo S, Wang YL, Li Y, Jin L, Xiong M, Ji QH, Wang J: **Significant SNPs have limited prediction ability for thyroid cancer.** *CANCER MEDICINE* 2014.

5. He Y, Cui Y, Wang W, Gu J, Guo S, Ma K, Luo X: **Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma.** *Neoplasia* 2011, **13:**841-853.

6. Flores K, Wolschin F, Corneveaux JJ, Allen AN, Huentelman MJ, Amdam GV: **Genome-wide association between DNA methylation and alternative splicing in an invertebrate.** *BMC genomics* 2012, **13:**480.

7. Zhao Y, Sun J, Zhang H, Guo S, Gu J, Wang W, Tang N, Zhou X, Yu J: **High-frequency aberrantly methylated targets in pancreatic adenocarcinoma identified via global DNA methylation analysis using methylCap-seq.** *Clinical epigenetics* 2014, **6:**18.

8. Laird PW: **The power and the promise of DNA methylation markers.** *Nat Rev Cancer* 2003, **3:**253-266.

9. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA: **A panel of sputum-based genomic marker for early detection of lung cancer.** *Cancer Prev Res (Phila)* 2010, **3:**1571-1578.

10. Zhu J, Yao X: **Use of DNA methylation for cancer detection: promises and challenges.** *Int J Biochem Cell Biol* 2009, **41:**147-154.

11. Zhao Y, Zhou H, Ma K, Sun J, Feng X, Geng J, Gu J, Wang W, Zhang H, He Y, et al: **Abnormal methylation of seven genes and their associations with clinical characteristics in early stage non-small cell lung cancer.** *Oncol Lett* 2013, **5:**1211-1218.

12. Anglim PP, Alonzo TA, Laird-Offringa IA: **DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update.** *Mol Cancer* 2008, **7:**81.

13. Nikolaidis G, Raji OY, Markopoulou S, Gosney JR, Bryan J, Warburton C, Walshaw M, Sheard J, Field JK, Liloglou T: **DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer.** *Cancer Res* 2012, **72:**5692-5701.

14. Guo S, Tan L, Pu W, Wu J, Xu K, Li Q, Ma Y, Xu J, Jin L, Wang J: **Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer.** *Clinical epigenetics* 2014, **6:**5.

15. Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, Liu C: **Removing batch effects in analysis of expression microarray data: an evaluation of six batch adjustment methods.** *Plos One* 2011, **6:**e17238.

16. Johnson WE, Li C, Rabinovic A: **Adjusting batch effects in microarray expression data using empirical Bayes methods.** *Biostatistics* 2007, **8:**118-127.

17. Edgar R, Domrachev M, Lash AE: **Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.** *Nucleic Acids Res* 2002, **30:**207-210.

18. El-Maarri O, Walier M, Behne F, van Uum J, Singer H, Diaz-Lacava A, Nusgen N, Niemann B, Watzka M, Reinsberg J, et al: **Methylation at global LINE-1 repeats in human blood are affected by gender but not by age or natural hormone cycles.** *PLoS One* 2011, **6:**e16252.

19. El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-Lacava A, Schwaab R, Wienker T, Oldenburg J: **Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males.** *Hum Genet* 2007, **122:**505-514.

20. Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA: **DNA methylation analysis: a powerful new tool for lung cancer diagnosis.** *Oncogene* 2002, **21:**5450-5461.

21. Heakal Y, Woll MP, Fox T, Seaton K, Levenson R, Kester M: **Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains.** *Cancer Biol Ther* 2011, **12:**427-435.

22. Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J: **Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation.** *Cancer Res* 2011, **71:**6817-6826.

23. Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, Ahmed-Zaid SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, et al: **Neurotensin receptor 1 determines the outcome of non-small cell lung cancer.** *Clin Cancer Res* 2010, **16:**4401-4410.

24. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P: **The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers.** *Biochimie* 2011, **93:**1369-1378.

25. Misawa K, Ueda Y, Kanazawa T, Misawa Y, Jang I, Brenner JC, Ogawa T, Takebayashi S, Grenman RA, Herman JG, et al: **Epigenetic inactivation of galanin receptor 1 in head and neck cancer.** *Clin Cancer Res* 2008, **14:**7604-7613.

26. Kanazawa T, Kommareddi PK, Iwashita T, Kumar B, Misawa K, Misawa Y, Jang I, Nair TS, Iino Y, Carey TE: **Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.** *Clin Cancer Res* 2009, **15:**2222-2230.

27. Henson BS, Neubig RR, Jang I, Ogawa T, Zhang Z, Carey TE, D'Silva NJ: **Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma.** *J Biol Chem* 2005, **280:**22564-22571.

28. Park JY, Helm JF, Zheng W, Ly QP, Hodul PJ, Centeno BA, Malafa MP: **Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer.** *Pancreas* 2008, **36:**e32-39.

29. Ueno M, Toyota M, Akino K, Suzuki H, Kusano M, Satoh A, Mita H, Sasaki Y, Nojima M, Yanagihara K, et al: **Aberrant methylation and histone deacetylation associated with silencing of SLC5A8 in gastric cancer.** *Tumour Biol* 2004, **25:**134-140.

30. Miyauchi S, Gopal E, Fei YJ, Ganapathy V: **Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids.** *J Biol Chem* 2004, **279:**13293-13296.

31. Gibbs AR, Thunnissen FB: **Histological typing of lung and pleural tumours: third edition.** *J Clin Pathol* 2001, **54:**498-499.

32. Edge SB, Compton CC: **The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.** *Ann Surg Oncol* 2010, **17:**1471-1474.

33. Zhao Y, Guo S, Sun J, Huang Z, Zhu T, Zhang H, Gu J, He Y, Wang W, Ma K, et al: **Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.** *PloS one* 2012, **7:**e35175.

34. Wang X, Wang L, Guo S, Bao Y, Ma Y, Yan F, Xu K, Xu Z, Jin L, Lu D, et al: **Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers.** *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 2013, **27:**4194-4203.

35. Wang YL, Feng SH, Guo SC, Wei WJ, Li DS, Wang Y, Wang X, Wang ZY, Ma YY, Jin L, et al: **Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population.** *Journal of medical genetics* 2013, **50:**689-695.

36. Dessau RB, Pipper CB: **[''R"--project for statistical computing].** *Ugeskr Laeger* 2008, **170:**328-330.

37. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al: **The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored.** *Nucleic Acids Res* 2011, **39:**D561-568.

## Figure legends

Figure 1. Sketch of the study design and pipeline.

Candidate biomarkers were selected from Meta-analysis to multiple high-throughput DNA methylation microarrays. Significant or best feature combination was screened in an independent validation study of NSCLC with MSD-SNuPET technique.

Figure 2. *Combat* treatment and MSD-SNuPET

Principal component analysis was applied to show the efficiency of the elimination of *ComBat*. Figure 2A, 2B, a total of 120 probe sets with DNA methylation values after background and quantile normalization in a set of 352 NSCLC and 106 normal samples. X and Y axes represent the first and second principal components (PC1 and PC2), respectively. Figures 2C-I were validation of the methylation status of the five candidate markers in an independent samples. Y-axis represents absolute DNA methylation percentage from MSD-SNuPET. *LINE-1* and Reference were taken as the positive and negative control for MSD-SNuPET.

## Tables and footnote

|  |  |
| --- | --- |
| Table 1. Characteristics of patients | |
|  | NSCLC = 150 |
| Age | 40 (IQR = 15-65) |
| Gender |  |
| Male | 120 |
| Female | 30 |
| Smoke Status |  |
| Non-smokers (never) | 41 |
| Smokers (ever) | 96 |
| Histology |  |
| Adenocarcinoma | 53 |
| Squamous cell carcinoma | 63 |
| others | 34 |
| Stage |  |
| I (IA,IB) | 42 (10,32) |
| II (IIA,IIB) | 48 (16,32) |
| III (IIIA,IIIB) | 46 (41,5) |
| IV | 2 |
| Differentiation |  |
| Well/Moderate | 74 |
| Poor | 30 |

Smokers include former and current smoker individuals. Others include adenosquamous carcinoma (ADSQ), bronchioloalveolar carcinoma, mucoepidermoid lung tumor, Sarcomatoid carcinoma. TNM Stages were assessed by the seventh edition of TNM classification criteria. Qualitative assessment of tumor differentiation was based on sum of the architecture score and cytologic atypia score (2 = well differentiated, 3 = moderately differentiated, 4 = poorly differentiated).

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Table 2. Differential Methylation in NSCLCs | | | | | | | | |
|  | AMP  (NSCLC) | AMP  (Control) | P-valuea | log10(OR) (95%CI) | P-valueb | Sen | Spe | AUC |
| *AGTR1* | 12.88% | 4.48% | 1.06E-07 | 3.49 (2.08, 4.91) | 1.30E-06 | 59.73% | 79.59% | 0.71 |
| *GALR1* | 18.31% | 2.91% | 6.58E-09 | 2.56 (1.5, 3.63) | 2.30E-06 | 46.98% | 85.03% | 0.67 |
| *NTSR1* | 9.37% | 0.56% | 1.09E-09 | 9.02 (5.48, 12.55) | 5.90E-07 | 44.30% | 94.56% | 0.70 |
| *SLC5A8* | 25.59% | 11.66% | 4.77E-12 | 3.80 (2.51, 5.09) | 7.80E-09 | 52.35% | 88.44% | 0.67 |
| *ZMYND10* | 6.95% | 12.82% | 1.08E-07 | -4.61 (-6.27, -2.95) | 5.20E-08 | 73.15% | 92.52% | 0.80 |
| *LINE-1* | 72.10% | 76.76% | 2.39E-12 | -10.3 (-13.5, -7.2) | 1.80E-10 | - | - | - |
| Reference | 1.78% | 1.83% | 2.85E-01 | -19.37 (-45.35, 6.62) | 0.14 | - | - | - |

Differential methylation analysis was conducted between 150 NSCLC and adjacent normal tissues. AMP: Average methylation percentage. P-valuea is the bonferroni adjusted P-value which were based on paired *t*-test compared the intensity of the methylation signals between case and control. log10(OR) and P-valueb represent log-transformed Odds ratio and p-value based on logistic regression adjusted by gender, age and smoking status. Reference site was a C site that was not in CpG site, therefore, no or low methylated signal would be detected and non-significant association should be detected between cancer and normal tissues. Sensitivity, specificity and AUC were calculated by logistic regression prediction model without adjustment for gender, age and smoking status.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Table 3. Diagnosis accuracy, sensitivity and specificity based on several classification methods with five-fold cross-validation | | | | | | |
|  | test | | | train | | |
|  | Sensitivity | Specificity | Accuracy | Sensitivity | Specificity | Accuracy |
| Logistic Regression | 0.791 | 0.993 | 0.891 | 0.775 | 0.969 | 0.871 |
| SVM | 0.897 | 0.977 | 0.937 | 0.855 | 0.941 | 0.897 |
| Random Forest | 0.934 | 0.928 | 0.931 | 0.890 | 0.886 | 0.886 |
| Bayes Tree | 0.911 | 0.976 | 0.944 | 0.863 | 0.957 | 0.909 |

Sensitivity, specificity and classification accuracy were its mean value in 5-fold validations with 1,000 replications. SVM represents support vector machines and Kernel Methods. In the main body of the manuscript, sensitivity, specificity and accuracy were derived from training result of the classification.